Lilly, S.A., Alcobendas, Spain.
ConfometRx, Santa Clara, CA, USA.
Nat Chem Biol. 2020 Oct;16(10):1105-1110. doi: 10.1038/s41589-020-0589-7. Epub 2020 Jul 20.
Drugs that promote the association of protein complexes are an emerging therapeutic strategy. We report discovery of a G protein-coupled receptor (GPCR) ligand that stabilizes an active state conformation by cooperatively binding both the receptor and orthosteric ligand, thereby acting as a 'molecular glue'. LSN3160440 is a positive allosteric modulator of the GLP-1R optimized to increase the affinity and efficacy of GLP-1(9-36), a proteolytic product of GLP-1(7-36). The compound enhances insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner. Cryo-electron microscopy determined the structure of the GLP-1R bound to LSN3160440 in complex with GLP-1 and heterotrimeric G. The modulator binds high in the helical bundle at an interface between TM1 and TM2, allowing access to the peptide ligand. Pharmacological characterization showed strong probe dependence of LSN3160440 for GLP-1(9-36) versus oxyntomodulin that is driven by a single residue. Our findings expand protein-protein modulation drug discovery to uncompetitive, active state stabilizers for peptide hormone receptors.
促进蛋白复合物结合的药物是一种新兴的治疗策略。我们报告了一种 G 蛋白偶联受体 (GPCR) 配体的发现,该配体通过协同结合受体和正位配体稳定活性状态构象,从而充当“分子胶”。LSN3160440 是一种优化后的 GLP-1R 的正变构调节剂,旨在增加 GLP-1(9-36)(GLP-1(7-36) 的蛋白水解产物)的亲和力和效力。该化合物以葡萄糖、配体和 GLP-1R 依赖的方式增强胰岛素分泌。冷冻电子显微镜确定了 GLP-1R 与 LSN3160440 结合的结构,该结构与 GLP-1 和异三聚体 G 形成复合物。调节剂结合在螺旋束的高位,位于 TM1 和 TM2 之间的界面上,允许肽配体进入。药理学特征表明,LSN3160440 对 GLP-1(9-36)的探针依赖性很强,而对 oxyntomodulin 的探针依赖性很弱,这种差异是由单个残基驱动的。我们的发现将蛋白-蛋白调节药物发现扩展到肽激素受体的非竞争性、活性状态稳定剂。